Clinical Outcome of Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation for the Treatment of Coronary Drug-Eluting Stent In-Stent Chronic Total Occlusion

[1] Bangalore S(2012)Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2873-2891

[2] Kumar S(2013)Drug-eluting coronary-artery stents N Engl J Med 368 254-265

[3] Fusaro M(2018)5-year outcome following randomized treatment of all-comers with zotarolimus-eluting resolute integrity and everolimus-eluting PROMUS element coronary stents: final report of the DUTCH PEERS (TWENTE II) Trial JACC Cardiovasc Interv 11 462-469

[4] Stefanini GG(2017)Biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: final 5-year report from the COMPARE II Trial (abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) JACC Cardiovasc Interv 10 1215-1221

[5] Holmes DR(2015)Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial Circ Cardiovasc Interv 8 e002230-1466

[6] Zocca P(2005)Success, safety, and mechanisms of failure of percutaneous coronary intervention for occlusive non-drug-eluting in-stent restenosis versus native artery total occlusion Am J Cardiol 95 1462-1971

[7] Kok MM(2020)Outcomes of percutaneous coronary intervention for in-stent chronic total occlusions: insights from the PROGRESS-CTO Registry JACC Cardiovasc Interv 13 1969-e479

[8] Tandjung K(2020)Clinical outcomes after percutaneous coronary intervention for in-stent chronic total occlusion EuroIntervention 16 e472-165

[9] Vlachojannis GJ(2015)Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients BMJ 351 h5392-3728

[10] Smits PC(2019)2018 ESC/EACTS Guidelines on myocardial revascularization Eur Heart J 40 87-3731

[1] Bangalore S(2012)Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2873-2891

[2] Kumar S(2013)Drug-eluting coronary-artery stents N Engl J Med 368 254-265

[3] Fusaro M(2018)5-year outcome following randomized treatment of all-comers with zotarolimus-eluting resolute integrity and everolimus-eluting PROMUS element coronary stents: final report of the DUTCH PEERS (TWENTE II) Trial JACC Cardiovasc Interv 11 462-469

[4] Stefanini GG(2017)Biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: final 5-year report from the COMPARE II Trial (abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) JACC Cardiovasc Interv 10 1215-1221

[5] Holmes DR(2015)Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial Circ Cardiovasc Interv 8 e002230-1466

[6] Zocca P(2005)Success, safety, and mechanisms of failure of percutaneous coronary intervention for occlusive non-drug-eluting in-stent restenosis versus native artery total occlusion Am J Cardiol 95 1462-1971

[7] Kok MM(2020)Outcomes of percutaneous coronary intervention for in-stent chronic total occlusions: insights from the PROGRESS-CTO Registry JACC Cardiovasc Interv 13 1969-e479

[8] Tandjung K(2020)Clinical outcomes after percutaneous coronary intervention for in-stent chronic total occlusion EuroIntervention 16 e472-165

[9] Vlachojannis GJ(2015)Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients BMJ 351 h5392-3728

[10] Smits PC(2019)2018 ESC/EACTS Guidelines on myocardial revascularization Eur Heart J 40 87-3731